Overview
Adenocarcinoma of the cervix uteri is a malignant neoplasm arising from the glandular (columnar) epithelial cells of the uterine cervix. It represents approximately 20-25% of all cervical cancers, with the remainder being predominantly squamous cell carcinomas. This cancer type has been increasing in both relative and absolute incidence over recent decades, particularly among younger women. It is strongly associated with persistent infection by high-risk human papillomavirus (HPV) types, especially HPV 18 and HPV 16, although a subset of cases may be HPV-independent. The disease primarily affects the reproductive system, originating in the endocervical canal. Key clinical features include abnormal vaginal bleeding (particularly postcoital bleeding), unusual vaginal discharge, and pelvic pain, though early-stage disease is often asymptomatic. As the tumor progresses, it may invade surrounding structures including the uterine body, parametrium, vagina, bladder, and rectum, and may metastasize to regional lymph nodes and distant organs. Adenocarcinoma of the cervix can be more difficult to detect on routine cervical screening (Pap smear) compared to squamous cell carcinoma because the glandular lesions often arise higher in the endocervical canal. Treatment depends on the stage at diagnosis and may include surgery (such as radical hysterectomy with pelvic lymphadenectomy for early-stage disease), radiation therapy, and chemotherapy. Concurrent chemoradiation with cisplatin-based regimens is the standard of care for locally advanced disease. Immunotherapy, particularly immune checkpoint inhibitors such as pembrolizumab, has emerged as an option for recurrent or metastatic disease, especially in tumors with PD-L1 expression or high microsatellite instability. HPV vaccination programs represent an important preventive strategy, as they target the high-risk HPV types most commonly associated with this malignancy.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsEunice Dube — PHASE4
Uganda Cancer Institute — PHASE2
Avacta Life Sciences Ltd — PHASE1
IDEAYA Biosciences — PHASE1
Hospices Civils de Lyon
Ming-an Yu — NA
National Cancer Institute (NCI) — PHASE3
Anusha Kalbasi — PHASE1
Tianjin Medical University Cancer Institute and Hospital — PHASE2
Centre Georges Francois Leclerc — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Adenocarcinoma of the cervix uteri.
9 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersUniversity of Alabama at Birmingham Cancer Center
📍 Birmingham, Alabama
University of Arkansas for Medical Sciences
📍 Little Rock, Arkansas
PCR Oncology
📍 Arroyo Grande, California
Mercy Hospital Fort Smith
📍 Fort Smith, Arkansas
Alta Bates Summit Medical Center-Herrick Campus
📍 Berkeley, California
Kaiser Permanente-Deer Valley Medical Center
📍 Antioch, California
Mills-Peninsula Medical Center
📍 Burlingame, California
Mayo Clinic in Arizona
📍 Scottsdale, Arizona
Travel Grants
No travel grants are currently matched to Adenocarcinoma of the cervix uteri.
Community
No community posts yet. Be the first to share your experience with Adenocarcinoma of the cervix uteri.
Start the conversation →Latest news about Adenocarcinoma of the cervix uteri
Disease timeline:
New recruiting trial: A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
New recruiting trial: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
New recruiting trial: TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
New recruiting trial: Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
New recruiting trial: Natural History Study of Children and Adults With Medullary Thyroid Cancer
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
New recruiting trial: Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
New recruiting trial: A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
New recruiting trial: Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
New recruiting trial: POP-UP: a Single-arm, Two-cohort Study: Trimodal Prehab for Upper GI and Pancreatic Cancer
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
New recruiting trial: A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.
A new clinical trial is recruiting patients for Adenocarcinoma of the cervix uteri
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Adenocarcinoma of the cervix uteri
What is Adenocarcinoma of the cervix uteri?
Adenocarcinoma of the cervix uteri is a malignant neoplasm arising from the glandular (columnar) epithelial cells of the uterine cervix. It represents approximately 20-25% of all cervical cancers, with the remainder being predominantly squamous cell carcinomas. This cancer type has been increasing in both relative and absolute incidence over recent decades, particularly among younger women. It is strongly associated with persistent infection by high-risk human papillomavirus (HPV) types, especially HPV 18 and HPV 16, although a subset of cases may be HPV-independent. The disease primarily aff
How is Adenocarcinoma of the cervix uteri inherited?
Adenocarcinoma of the cervix uteri follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Adenocarcinoma of the cervix uteri typically begin?
Typical onset of Adenocarcinoma of the cervix uteri is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Adenocarcinoma of the cervix uteri?
Yes — 9 recruiting clinical trials are currently listed for Adenocarcinoma of the cervix uteri on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Adenocarcinoma of the cervix uteri?
25 specialists and care centers treating Adenocarcinoma of the cervix uteri are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.